ESOT 01
Alternative Names: ESO-T01Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator EsoBiotec
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Multiple myeloma
Most Recent Events
- 27 Jan 2025 Pregene ShenZhen Biotechnology plans a phase 0 trial for Multiple myeloma (Second-line therapy or greater) in China (Parenteral), in January 2025 (NCT06791681)
- 15 Jan 2025 Chromatin Bioscience and EsoBiotec enters into a collaboration agreement for chromatinLENS platform
- 08 Jan 2025 Efficacy, adverse event and pharmacokinetics data from phase 0 trial in Multiple myeloma released by EsoBiotec